drugset / Trial / NCT05444478
Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
This study intends to evaluate the efficacy and safety of microwave ablation combined lenvatinib simultaneously for recurrent HCC
Timeline
- Start
- 2022-07-01
- Primary completion
- 2025-07-01
- Completion
- 2027-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | 80 mg | — |
| Subject | Lenvatinib | Small molecule | 120 mg | — |